SIR Issues a Statement of Commitment in Support of Diversity

“We Believe in Diversity and Inclusion”

June 3, 2020

SIR (Society of Interventional Radiology) President Michael D. Dake, MD, FSIR, and Diversity and Inclusiveness Group Chair Paul J. Rochon, MD, FSIR, issued the following statement on supporting diversity and combating racial inequality in America.

Humanity has been dealt with many challenges this year. While COVID-19 has undoubtedly received much of our attention, we suffer from another pandemic that remains a structural and pernicious threat—racism. The Society of Interventional Radiology (SIR) will not be silent on this issue.

We denounce any act of hatred and bigotry on the basis of race, ethnicity, religion, sexual orientation, or gender identity. We denounce the long history of hatred and violence against the Black community and support our Black patients, physicians, trainees, nurses, technologists, industry partners, staff, and administrators. We need to stand together in strength and work with a common purpose to realize a more diverse, equitable, and inclusive organization.

We commit to antiracist efforts, policies, and programs that aim to increase the numbers of underrepresented minorities and women within our specialty. Our GEMS program supports diversity in interventional radiology by providing a travel grant for medical students from diverse backgrounds who desire to participate in a visiting clerkship in interventional radiology (IR) outside of their home institution.

We value a culture of inclusion in which all members of the IR community are accepted, respected, and embraced. The society’s IAmIR campaign has both celebrated and drawn attention to diversity within the specialty. SIR has microgrants that support research performed by female and underrepresented minority scientists and a speakers’ bureau to ensure IRs of color are tapped as experts in their field at scientific meetings.

We strongly support the need to reduce and eliminate health disparities that affect our Black patients and other patients of color. SIR’s Diversity and Inclusiveness Group Task Force has been working for several years to ensure that these issues are a vital part of our strategic plan.

We call upon our membership and affiliates to take this time to remember the families and communities of George Floyd, Breonna Taylor, Ahmaud Arbery, and many others who have been subject to unconscionable acts of discrimination and hate. We ask that everyone look into his or her heart to understand the overdue need for change in the nation. With our intentional efforts, SIR calls to action the continuing need to develop strategies to ensure justice, diversity, equity, and inclusion.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”